[A17-54] Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24
Last updated 17.11.2017
Project no.:
A17-54
Commission:
Commission awarded on 09.10.2017 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with squamous-cell carcinoma of the head and neck with progression during/after platinum-based therapy
Result of dossier assessment:
Conclusion of dossier assessment A17-24 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-40 | Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A17-24 | Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-11-17 A G-BA decision was published.